Payment overview · 2025
General Payments
$1,575.15
79 reported records · 20 companies
Healthcare provider profile · identity verified
Mark J. Bergman, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine|Cardiovascular Disease · HUNTINGTON, NY · NPI 1063512002
Verified facts
What the public records show
CMS Open Payments records show Mark J. Bergman, M.D. received $1,575.15 in general payments during 2025 across 79 reported records.
Novartis Pharmaceuticals Corporation accounted for 15.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 33 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Edarbi, Eliquis, Farxiga, Jardiance, Mounjaro, Nexletol, Ozempic, Synthroid, Wegovy.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 155 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 88 claims for Farxiga by this doctor in 2024.
Azurity Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported EDARBI as an associated drug or biological on 1140 records involving 805 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Edarbi by this doctor in 2024.
Azurity Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported EDARBYCLOR as an associated drug or biological on 283 records involving 215 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Edarbyclor by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 106 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 251 claims for Eliquis by this doctor in 2024.
Esperion Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXLETOL as an associated drug or biological on 24230 records involving 12642 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Nexletol by this doctor in 2024.
Esperion Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXLIZET as an associated drug or biological on 63 records involving 47 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Nexlizet by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 106 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 131 claims for Mounjaro by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 85 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 75 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Wegovy as an associated drug or biological on 183056 records involving 75256 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Wegovy by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 251 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $249.77 | 15.9% | 9 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $207.84 | 13.2% | 11 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $161.93 | 10.3% | 14 | 2025 |
| Azurity Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $130.81 | 8.3% | 7 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $113.30 | 7.2% | 6 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $96.29 | 6.1% | 4 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $82.54 | 5.2% | 4 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $82.04 | 5.2% | 3 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $67.61 | 4.3% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $55.80 | 3.5% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $48.18 | 3.1% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $44.24 | 2.8% | 2 | 2025 |
| MEDICOMP INC | Unresolved — no canonical attribution shown | $39.20 | 2.5% | 1 | 2025 |
| HEARTFLOW, INC. | Unresolved — no canonical attribution shown | $37.77 | 2.4% | 2 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $28.99 | 1.8% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $28.53 | 1.8% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $28.19 | 1.8% | 2 | 2025 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Unresolved — no canonical attribution shown | $27.05 | 1.7% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $24.85 | 1.6% | 1 | 2025 |
| BridgeBio Pharma, Inc. | Unresolved — no canonical attribution shown | $20.22 | 1.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,575.15 | 79 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $249.77 | 9 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $207.84 | 11 | 2025 |
Source payment records
|
|||||
| EDARBI Normalized: edarbi |
Drug | Azurity Pharmaceuticals, Inc. | $130.81 | 7 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C., PFIZER INC. | $97.83 | 9 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $93.33 | 5 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $82.54 | 4 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $82.04 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $72.15 | 3 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $71.98 | 5 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $71.98 | 5 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $71.98 | 5 | 2025 |
Source payment records
|
|||||
| SYNTHROID Normalized: synthroid |
Drug | ABBVIE INC. | $48.18 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $44.24 | 2 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $44.24 | 2 | 2025 |
Source payment records
|
|||||
| TELEPATCH CARDIAC MONITOR Normalized: telepatch cardiac monitor |
Device | MEDICOMP INC | $39.20 | 1 | 2025 |
Source payment records
|
|||||
| FFRct Normalized: ffrct |
Device | HEARTFLOW, INC. | $37.77 | 2 | 2025 |
Source payment records
|
|||||
| VYNDAQEL Normalized: vyndaqel |
Drug | PFIZER INC. | $35.53 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $33.73 | 6 | 2025 |
Source payment records
|
|||||
| WATCHMAN FLX Normalized: watchman flx |
Device | Boston Scientific Corporation | $28.99 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $28.53 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $28.19 | 2 | 2025 |
Source payment records
|
|||||
| LifeVest Normalized: lifevest |
Device | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $27.05 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $24.85 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $24.85 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $24.36 | 1 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $24.20 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $24.14 | 1 | 2025 |
Source payment records
|
|||||
| WAINUA Normalized: wainua |
Drug | AstraZeneca Pharmaceuticals LP | $22.96 | 1 | 2025 |
Source payment records
|
|||||
| Attruby Normalized: attruby |
Drug | BridgeBio Pharma, Inc. | $20.22 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $19.97 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $19.97 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $18.25 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $14.59 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| EDARBI edarbi |
2025 | Edarbi | 2024 | 35 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 251 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 88 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 106 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 131 | exact normalized | Medicare Part D |
| NEXLETOL nexletol |
2025 | Nexletol | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 75 | exact normalized | Medicare Part D |
| SYNTHROID synthroid |
2025 | Synthroid | 2024 | 155 | exact normalized | Medicare Part D |
| Wegovy wegovy |
2025 | Wegovy | 2024 | 54 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
155 | 43 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
88 | 24 |
| Azurity Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | EDARBI open payments reported associated product |
CMS Open Payments — General Payments 1140 supporting records · 805 recipient NPIs · example record 1242666830 |
Edarbi · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| Azurity Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | EDARBYCLOR open payments reported associated product |
CMS Open Payments — General Payments 283 supporting records · 215 recipient NPIs · example record 1242666846 |
Edarbyclor · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
106 | 27 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
251 | 63 |
| Esperion Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | NEXLETOL open payments reported associated product |
CMS Open Payments — General Payments 24230 supporting records · 12642 recipient NPIs · example record 1243949989 |
Nexletol · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Esperion Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | NEXLIZET open payments reported associated product |
CMS Open Payments — General Payments 63 supporting records · 47 recipient NPIs · example record 1243951667 |
Nexlizet · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
106 | 27 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
131 | 24 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
85 | 20 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
75 | 16 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Wegovy open payments reported associated product |
CMS Open Payments — General Payments 183056 supporting records · 75256 recipient NPIs · example record 1188130070 |
Wegovy · 2024 Exact normalized brand match · 1 Part D row |
54 | 15 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
251 | 63 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 734 | 214 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 594 | 179 |
| Metoprolol Succinate | Metoprolol Succinate | 507 | 160 |
| Amlodipine Besylate | Amlodipine Besylate | 503 | 142 |
| Levothyroxine Sodium | Levothyroxine Sodium | 383 | 105 |
| Losartan Potassium | Losartan Potassium | 338 | 103 |
| Alprazolam | Alprazolam | 313 | 107 |
| Zolpidem Tartrate | Zolpidem Tartrate | 284 | 55 |
| Simvastatin | Simvastatin | 261 | 73 |
| Eliquis | Apixaban | 251 | 63 |
| Clopidogrel | Clopidogrel Bisulfate | 237 | 77 |
| Hydrochlorothiazide | Hydrochlorothiazide | 228 | 61 |
| Omeprazole | Omeprazole | 199 | 66 |
| Escitalopram Oxalate | Escitalopram Oxalate | 183 | 51 |
| Furosemide | Furosemide | 183 | 71 |
| Metformin Hcl | Metformin Hcl | 181 | 54 |
| Synthroid | Levothyroxine Sodium | 155 | 43 |
| Carvedilol | Carvedilol | 152 | 42 |
| Potassium Chloride | Potassium Chloride | 144 | 54 |
| Metoprolol Tartrate | Metoprolol Tartrate | 142 | 42 |
| Xarelto | Rivaroxaban | 138 | 35 |
| Atenolol | Atenolol | 133 | 38 |
| Mounjaro | Tirzepatide | 131 | 24 |
| Lisinopril | Lisinopril | 127 | 42 |
| Repatha Sureclick | Evolocumab | 127 | 19 |
| Valsartan | Valsartan | 123 | 38 |
| Ezetimibe | Ezetimibe | 108 | 31 |
| Jardiance | Empagliflozin | 106 | 27 |
| Pantoprazole Sodium | Pantoprazole Sodium | 104 | 39 |
| Gabapentin | Gabapentin | 99 | 34 |
| Sertraline Hcl | Sertraline Hcl | 98 | 27 |
| Allopurinol | Allopurinol | 92 | 29 |
| Azithromycin | Azithromycin | 89 | 56 |
| Farxiga | Dapagliflozin Propanediol | 88 | 24 |
| Nebivolol Hcl | Nebivolol Hcl | 86 | 21 |
| Entresto | Sacubitril/Valsartan | 85 | 20 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 80 | 25 |
| Montelukast Sodium | Montelukast Sodium | 78 | 25 |
| Pravastatin Sodium | Pravastatin Sodium | 77 | 22 |
| Ozempic | Semaglutide | 75 | 16 |
| Tamsulosin Hcl | Tamsulosin Hcl | 73 | 27 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 72 | 27 |
| Diazepam | Diazepam | 72 | 22 |
| Fenofibrate | Fenofibrate | 70 | 20 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 69 | 21 |
| Amiodarone Hcl | Amiodarone Hcl | 67 | 18 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 67 | 21 |
| Spironolactone | Spironolactone | 65 | 23 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 65 | 20 |
| Meloxicam | Meloxicam | 64 | 18 |
| Vascepa | Icosapent Ethyl | 57 | 11 |
| Clonazepam | Clonazepam | 56 | 14 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 55 | 38 |
| Finasteride | Finasteride | 55 | 14 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 54 | 18 |
| Ramipril | Ramipril | 54 | 12 |
| Wegovy | Semaglutide | 54 | 15 |
| Warfarin Sodium | Warfarin Sodium | 53 | 14 |
| Lorazepam | Lorazepam | 51 | suppressed |
| Methylprednisolone | Methylprednisolone | 51 | 39 |
| Donepezil Hcl | Donepezil Hcl | 48 | 18 |
| Fluticasone Propionate | Fluticasone Propionate | 47 | 21 |
| Irbesartan | Irbesartan | 45 | 12 |
| Sumatriptan Succinate | Sumatriptan Succinate | 44 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 42 | 28 |
| Famotidine | Famotidine | 42 | 16 |
| Digoxin | Digoxin | 38 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 38 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 37 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 37 | 15 |
| Edarbi | Azilsartan Medoxomil | 35 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 34 | 14 |
| Klor-Con M10 | Potassium Chloride | 34 | 13 |
| Eszopiclone | Eszopiclone | 33 | suppressed |
| Edarbyclor | Azilsartan Med/Chlorthalidone | 32 | suppressed |
| Nystatin | Nystatin | 31 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 30 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 30 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 29 | suppressed |
| Ranolazine Er | Ranolazine | 29 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 28 | suppressed |
| Pregabalin | Pregabalin | 28 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 27 | 24 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 26 | 22 |
| Metformin Hcl Er | Metformin Hcl | 26 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 26 | 11 |
| Paroxetine Hcl | Paroxetine Hcl | 26 | suppressed |
| Prednisone | Prednisone | 26 | 12 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 25 | suppressed |
| Verapamil Er | Verapamil Hcl | 25 | suppressed |
| Klor-Con M20 | Potassium Chloride | 24 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 23 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 23 | suppressed |
| Colchicine | Colchicine | 23 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 23 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 23 | 19 |
| Prasugrel Hcl | Prasugrel Hcl | 23 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 23 | 13 |
| Glipizide Er | Glipizide | 22 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 22 | suppressed |
| Nexletol | Bempedoic Acid | 22 | suppressed |
| Bupropion Xl | Bupropion Hcl | 21 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 21 | suppressed |
| Pitavastatin Calcium | Pitavastatin Calcium | 21 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 20 | suppressed |
| Tacrolimus | Tacrolimus | 20 | suppressed |
| Torsemide | Torsemide | 20 | suppressed |
| Chlorthalidone | Chlorthalidone | 19 | suppressed |
| Dabigatran Etexilate | Dabigatran Etexilate Mesylate | 19 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 19 | suppressed |
| Brilinta | Ticagrelor | 18 | suppressed |
| Ketoconazole | Ketoconazole | 18 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 18 | suppressed |
| Amoxicillin | Amoxicillin | 17 | 12 |
| Baclofen | Baclofen | 17 | suppressed |
| Bumetanide | Bumetanide | 17 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 17 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 17 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 17 | suppressed |
| Telmisartan | Telmisartan | 17 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 16 | suppressed |
| Chlordiazepoxide-Amitriptyline | Amitriptyline/Chlordiazepoxide | 16 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 16 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 16 | suppressed |
| Nexlizet | Bempedoic Acid/Ezetimibe | 16 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 15 | 15 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 15 | suppressed |
| Bystolic | Nebivolol Hcl | 14 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 14 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 14 | suppressed |
| Fluconazole | Fluconazole | 14 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 14 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 13 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 13 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 13 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 13 | suppressed |
| Januvia | Sitagliptin Phosphate | 13 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 13 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 13 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 12 | suppressed |
| Hydrocortisone | Hydrocortisone | 12 | suppressed |
| Metronidazole | Metronidazole | 12 | suppressed |
| Exforge | Amlodipine Besylate/Valsartan | 11 | suppressed |
| Gemfibrozil | Gemfibrozil | 11 | suppressed |
| Glimepiride | Glimepiride | 11 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 11 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 11 | suppressed |
| Lidocaine | Lidocaine | 11 | suppressed |
| Livalo | Pitavastatin Calcium | 11 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 11 | suppressed |
| Memantine Hcl | Memantine Hcl | 11 | suppressed |
| Nifedipine Er | Nifedipine | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,575.15 · 79 records | Novartis Pharmaceuticals Corporation | ABRYSVO, AREXVY, Attruby, BREZTRI, CAMZYOS, CAPVAXIVE, COMIRNATY, EDARBI, ELIQUIS, FARXIGA, FFRct, GARDASIL 9, GEMTESA, JARDIANCE, Kerendia, LEQVIO, LifeVest, MOUNJARO, NEXLETOL, NURTEC ODT, Ozempic, PREVNAR 20, REPATHA, SHINGRIX, SYNTHROID, TELEPATCH CARDIAC MONITOR, UBRELVY, VERQUVO, VYNDAQEL, WAINUA, WATCHMAN FLX, Wegovy, ZEPBOUND | 16 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Edarbi play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error